Smith & Nephew plc (SNN) Cash Flow Statement

The wide oscillation in OCF/NI, from 0.66 to 5.67, suggests that net income is not a reliable proxy for cash generation in any given quarter. The 2023Q2 trough, where OCF was only 66% of net income, likely reflects a significant working capital outflow, while the 2022Q4 peak of 5.67 implies a large release of cash from operations relative to a depressed net income. This pattern indicates that accruals and working capital swings, not core profitability, drive quarterly cash conversion, warranting a focus on annual trends rather than quarterly snapshots.

The FCF margin shows a clear seasonal pattern: Q4 quarters (2025Q4: 18.6%, 2024Q4: 18.1%) are robust, while Q2 quarters are weak (2026Q2: 8.4%, 2024Q2: 2.3%, 2023Q2: -2.0%). This suggests that working capital dynamics, likely inventory builds and receivable timing, depress cash flow in the first half of the year. The 2026Q2 FCF margin of 8.4% is an improvement over the 2024Q2 trough, but it remains below the 2025Q4 peak, indicating that the company has not yet achieved consistent quarterly cash generation.

The capital intensity of approximately 7% of revenue is consistent with a medical device company that must maintain a vast inventory of surgical instruments at hospital sites. The Q4 peaks in CapEx/Revenue (9.2% in 2025Q4 and 2023Q4) may indicate a deliberate year-end investment cycle to refresh or expand the instrument tray fleet, which is critical for supporting elective procedures. This spending is likely a mix of maintenance and growth capex, as the company invests in robotics and cementless implants, but the consistent level suggests it is a structural cost of doing business rather than a discretionary growth initiative.

The large negative working capital changes in Q2 quarters (2022Q2: -$344M, 2024Q2: -$163M, 2023Q2: -$201M) suggest that the company builds inventory and extends receivables during the first half of the year, likely in anticipation of higher procedure volumes in the second half. The positive working capital change in 2025Q4 (+$82M) indicates a release of cash, possibly from improved collections or inventory reduction. This pattern implies that SNN's cash flow is heavily influenced by its ability to manage its surgical tray inventory and hospital receivables, and investors should monitor these swings as a leading indicator of cash generation.

The capital deployment strategy appears to have shifted in recent quarters, with a significant $502M buyback in 2025Q4 and a $221M acquisition in 2026Q2, while dividends have been maintained at roughly $200M per quarter. This suggests that management is using cash flow to return capital to shareholders and pursue bolt-on acquisitions, consistent with the '12-Point Plan' focus on growth. However, the sustainability of this deployment is questionable given the volatile FCF, and the elevated debt load of ~$3.32B may constrain future flexibility if cash generation does not improve.

The cumulative operating cash flow of $4.31B is roughly double the cumulative net income of $2.15B, indicating that SNN's cash generation has been strong on a cumulative basis, but the quarterly volatility obscures this. The gap between net income and OCF is primarily due to non-cash charges like D&A (which totaled ~$2.7B over the period) and working capital swings. This suggests that earnings quality is acceptable over the long term, but the timing of cash flows is unpredictable, which may affect the company's ability to consistently fund capital returns.